Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Payables (2017 - 2025)

Aclaris Therapeutics has reported Payables over the past 9 years, most recently at $13.2 million for Q4 2025.

  • Quarterly results put Payables at $13.2 million for Q4 2025, up 180.55% from a year ago — trailing twelve months through Dec 2025 was $13.2 million (up 180.55% YoY), and the annual figure for FY2025 was $13.2 million, up 180.55%.
  • Payables for Q4 2025 was $13.2 million at Aclaris Therapeutics, up from $9.2 million in the prior quarter.
  • Over the last five years, Payables for ACRS hit a ceiling of $13.2 million in Q4 2025 and a floor of $4.2 million in Q2 2021.
  • Median Payables over the past 5 years was $8.2 million (2022), compared with a mean of $8.3 million.
  • Biggest five-year swings in Payables: plummeted 47.17% in 2024 and later skyrocketed 180.55% in 2025.
  • Aclaris Therapeutics' Payables stood at $10.0 million in 2021, then grew by 3.67% to $10.4 million in 2022, then fell by 14.23% to $8.9 million in 2023, then tumbled by 47.17% to $4.7 million in 2024, then skyrocketed by 180.55% to $13.2 million in 2025.
  • The last three reported values for Payables were $13.2 million (Q4 2025), $9.2 million (Q3 2025), and $8.8 million (Q2 2025) per Business Quant data.